Pilot Study Assessing the Safety, Tolerability, Compliance and Efficacy of Twice Daily Dosed Pylera [tripotassium dicitrato bismuthate/tetracycline/metronidazole] Plus Omeprazole as a First Line Treatment of Helicobacter Pylori Infection

Trial Profile

Pilot Study Assessing the Safety, Tolerability, Compliance and Efficacy of Twice Daily Dosed Pylera [tripotassium dicitrato bismuthate/tetracycline/metronidazole] Plus Omeprazole as a First Line Treatment of Helicobacter Pylori Infection

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Omeprazole; Tripotassium dicitrato bismuthate/tetracycline/metronidazole
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use
  • Sponsors Adare Pharmaceuticals
  • Most Recent Events

    • 17 Dec 2008 Status changed from not yet recruiting to withdrawn prior to recruitment.
    • 30 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top